BioAlliance Pharma: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at June 30, 2013
July 05 2013 - 11:45AM
Business Wire
Regulatory News:
BioAlliance Pharma (Paris:BIO):
Pursuant to article L.233-8 II of the Code de commerce (the
French Commercial Code) and article 223-16 of the Règlement
général de l’Autorité des Marchés Financiers (Regulation of the
French stock market authority):
Date Total number of outstanding shares Total number
of voting rights June 30, 2013 18,159,715
Theoretical number of voting rights:
18,159,715(including treasury shares)
Number of real voting rights:
18,134,437(without treasury shares)
About BioAlliance Pharma
Dedicated to Specialty Pharma and Orphan products in cancer
treatment and in supportive care, with a focus on drug resistance,
BioAlliance conceives and develops innovative products, for
specialty markets especially in the hospital setting and for orphan
or rare diseases.Created in 1997 and introduced to the Euronext
Paris market in 2005, BioAlliance Pharma’s ambition is to become a
leading player in these fields by coupling innovation to patient
needs. The company’s teams have the key competencies required to
identify, develop and register drugs in Europe and USA; the
products’ commercialization rights are licensed to international
commercial partners invested in the hospital setting. In areas
where medical needs are insufficiently met, its targeted approaches
help overcome drug resistance and improve patient health &
quality of life. For more information, visit the BioAlliance Pharma
web site at www.bioalliancepharma.com.
BioAlliance Pharma SAJudith Gréciet, CEOTel.: +33 1 45 58
76 01Judith.greciet@bioalliancepharma.comorNicolas Fellmann,
CFOTel.: +33 1 45 58 71
00nicolas.fellmann@bioalliancepharma.comorALIZE RPCaroline
Carmagnol, Tel.: +33 6 64 18 99 59caroline@alizerp.com
Biotest (TG:BIO)
Historical Stock Chart
From Oct 2024 to Nov 2024
Biotest (TG:BIO)
Historical Stock Chart
From Nov 2023 to Nov 2024
